Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
Focus on core therapeutic areas of Oncology, Rare Disease and Neuroscience Commitment to invest in R&D supported by SG&A efficiencies Priority on External Innovation strategy to build sustainable pipeline for future growth Regulatory News: Ipsen (Euronext: IP...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the United States Food and Drug Administration (FDA) has granted the company Fast Track designation for irinotecan liposome injection (ONIVYDE®) in study patients with small cell lung cancer (SCLC) who progresse...
A Phase 2 clinical trial, ACROBAT Edge, evaluating Crinetics Pharmaceuticals' (CRNX) lead candidate paltusotine (formerly CRN00808) for the treatment of acromegaly met the primary endpoint. Specifically, once-daily oral doses of paltusotine maintained insulin-like growth factor-1 (IGF-1) leve...
Ipsen S.A. (IPSEY): Q3 Revenue of €633.3M (-1.8% Y/Y)2020 guidance: Group sales growth greater than +2.0% at constant currency, with an expected negative impact of 1.5% from currencies based on the level of exchange rates at the end of September, Core Operating margin greater than...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced sales for the third quarter of 2020. Q3 2020 Group sales growth of +2.2% 1 at constant exchange rates and decrease of -1.8% as reported, driven by Spe...
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200924005822/en/ Philippe Lopes-Fernandes, Executive Vice President, Chief Business Officer, Ipsen (Photo: Business Wire) Ipsen (Euronext: IP...
Cabometyx ® in combination with Opdivo ® showed superior overall survival and doubled median progression-free survival and objective response rate versus sunitinib, and had a favorable safety profile Efficacy benefits were observed across key patient subgroups, including al...
Increasing the dose frequency of lanreotidefrom monthly to bi-monthly achieved a progression-free survival of 8.3 months in patients with progressive midgut neuroendocrine tumors (NETs) and 5.6 months in patients with progressive pancreatic NETs These results show no new safety signals...
IPSEN ( OTCPK:IPSEY ) discloses a share buyback of 5,280 shares between September 7 and September 11. More news on: Ipsen S.A., , Read more ...
17 abstracts 1 to be shared, spanning a wide range of different cancer types, therapies and clinical study and real-world evidence designs Presentations will feature promising data across multiple cancers, including renal cell carcinoma, small cell lung cancer, pancreatic ductal ad...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...